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Background: We evaluated the frequency and prognostic impact of meningeal dissemination (MD) in
immunocompetent adult patients with primary central nervous system lymphoma treated in a randomized phase III trial.
Patients and methods: MD was evaluated at study entry and deﬁned by lymphoma proof in the meningeal
compartment detected by at least one of the following methods: cerebrospinal ﬂuid (CSF) cytomorphology, detection of
clonal B cells by IgH PCR in CSF or contrast enhancement of the leptomeninges on magnetic resonance imaging
(MRI).
Results: Data on MD were available in 415 patients, of those, MD was detected in 65 (15.7%): in 44/361 (12.2%) by
CSF cytomorphology, in 16/152 (10.5%) by PCR and in 17/415 (4.1%) by MRI. Major patients’ characteristics and
therapy did not signiﬁcantly differ between patients with MD (MD+) versus those without MD (MD−). There was a
signiﬁcant correlation of MD with CSF pleocytosis (>5/μl; P < 0.0001), but no correlation with CSF protein elevation (>45
mg/dl). Median progression-free survival was 6.7 months [95% conﬁdence interval (CI) 0–14.5] in MD+ and 8.3 months
(5.7–10.8) in MD− patients (P = 0.95); median overall survival was 21.5 months (95% CI 16.8–26.1) and 24.9 months
(17.5–32.3), respectively (P = 0.98).
Conclusion: MD was detected infrequently and had no impact on outcome in this trial.
Key words: cerebrospinal ﬂuid, meningeal dissemination, primary CNS lymphoma
introduction
Primary central nervous system lymphoma (PCNSL) usually
manifests as an intracerebral mass. The incidence of meningeal
dissemination (MD) in PCNSL is not exactly known. A wide
frequency range of 7%–42% has been reported, depending on
diagnostic methods applied, number of cerebrospinal ﬂuid
(CSF) examinations and inclusion of both newly diagnosed
and recurrent patients in the analysis [1–12]. An optimal
diagnostic CSF work-up has not been established in PCNSL
with CSF cytomorphologic evaluation still being regarded the
gold standard. In studies comparing CSF cytomorphology with
other diagnostic methods, a strikingly high rate of discordant
results was observed [13, 14].
The prognostic impact of MD in PCNSL has not been
sufﬁciently evaluated either. Whereas no impact of
cytomorphologically conﬁrmed MD has been reported in
several trials [1, 2, 8, 10, 11], a negative impact was found by
others [7, 14]. Due to the rarity of PCNSL and the relatively
low frequency of MD diagnosed by routine methods, it seems
probable that the series published thus far were too small to
detect signiﬁcant differences in outcome between MD+ and
MD− patients. Moreover, the retrospective analyses including
larger patients’ numbers might have been hampered by
heterogenous treatments frequently not containing high-dose
methotrexate (HDMTX). The present analysis is the ﬁrst to
evaluate MD on a large prospective cohort treated within one
protocol.
methods
patients and treatment
As previously reported [15], 526 eligible patients with newly diagnosed
PCNSL were enrolled at 75 centers and treated between May 2000 and May
2009. Inclusion criteria were immunocompetent adult patients with
histologically or cytologically (in CSF) conﬁrmed PCNSL, Karnofsky
performance score (KPS) >30 when due to PCNSL or >50 when due to
other conditions, creatinine clearence ≥50 ml/min and written informed
consent. Patients were randomly allocated to receive ﬁrst-line
chemotherapy based on HDMTX with or without subsequent whole-brain
radiotherapy (WBRT), with stratiﬁcation by age (<60 versus ≥60 years) and
institution (Berlin versus Tübingen versus all other sites). Between May
2000 and August 2006, study therapy consisted of HDMTX (4 g/m2 as a
4-h i.v. infusion with dose reduction according to creatinine clearence) on
day 1 of six 14-day cycles; thereafter, patients were to receive HDMTX
plus ifosfamide (1·5 g/m2) on days 3–5 of six 14-day cycles. In those
assigned to receive ﬁrst-line chemotherapy followed by radiotherapy,
WBRT was to be given at a total dose of 45 Gy. Patients allocated to ﬁrst-
line chemotherapy without WBRT who had not achieved complete
response were given high-dose cytarabine (2 × 3 g/m2 on days 1–2 of 22-
day cycles). Intrathecal chemotherapy was not included in the treatment
protocol.
The study protocol was approved by local institutional review boards or
ethics committees. All participants gave written informed consent.
Preliminary data concerning CSF diagnostics in 116 [16] and 282
patients [13] included in the G-PCNSL-SG1 trial have been published
before.
CSF analysis
CSF was obtained by single lumbar puncture before treatment and
evaluated using standard methods for cell count, cytomorphology and
protein immediately after sampling at the treating institution. Each sample
was interpreted by an experienced hematopathologist or neuropathologist.
Normal values were deﬁned as follows: CSF cells ≤5/μl and CSF protein
≤45 mg/dl. CSF cytomorphology was termed positive only for conclusive
detection of lymphoma cells. Patients with suspicious cytomorphology
were regarded negative.
PCR was carried out in patients with B-cell lymphoma only. A sample
of 1.5–5 ml (median 3.5 ml) of native CSF was sent over night at room
temperature to a central molecular biological laboratory. Here, DNA was
extracted from cell pellets after centrifugation at the day of arrival using
commercially available kits (Qiagen; Qiagen, Hilden, Germany) and stored
at room temperature until PCR analysis. All DNA extracts were controlled
for their suitability as templates for IgH PCR by determination of quantity
(NanoDrop; Thermo Fisher Scientiﬁc, Wilmington, DE) and quality
(quality control PCR) [17]. Until March 2006, PCR was carried out as
described previously [6]. Thereafter, PCR was carried out according to the
BIOMED-2 protocol [17]. In each PCR run, positive (DNA from a B cell
line) and negative controls (sterile water) and polyclonal (tonsilar DNA)
controls were included. All specimens were ampliﬁed at least twice in
independent PCR runs; the products were subjected to an automated
ﬂuorescent fragment analysis (GeneScan; ABI3130). A monoclonal pattern
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was deﬁned as single or dominating amplicon of identical size in repetitive
experiments, whereas multiple peaks characterized polyclonality.
neuroimaging
Brain magnetic resonance imaging (MRI) was obtained before treatment
and locally reviewed by an experienced neuroradiologist. All examinations
included T1- and T2-weighted sequences and contrast-enhanced studies on
various MR scanners with ﬁeld strengths of 1.0–1.5 T. MD on MRI was
deﬁned as contrast enhancement of the leptomeninges.
deﬁnition of MD
Patients were regarded having MD (MD+) if at least one of the following
conditions was fulﬁlled: positive CSF cytomorphology, monoclonal IgH
PCR pattern or typical contrast enhancement on MRI. Patients without
contrast enhancement and no data on CSF examination were classiﬁed as
MD not determined.
statistics
For statistical analysis, patient pretherapeutic characteristics were grouped
according to prognostic factors previously published: age, KPS, the
Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic score (class
1 patients <50 years, class 2 patients ≥50 and KPS≥ 70, class 3 patients
≥50 and KPS < 70) [11], lactate dehydrogenase (LDH) in serum, number of
brain lesions (0–1 and ≥2) and steroids before diagnostics. Whereas in the
descriptions always three groups (MD+, MD−, MD status unknown) are
presented, the tests of signiﬁcance were carried out only between MD+ and
MD− patients. Progression-free survival (PFS) was deﬁned as the time
from study entry to ﬁrst progression or death from any cause. Overall
survival (OS) was deﬁned as the time from study entry to death. PFS and
OS were estimated by the Kaplan–Meier method. Group comparisons were
carried out using the log-rank test. Distribution of patients characteristics
to different groups was analyzed by the chi-square test. MD status and CSF
pleocytosis or elevated CSF protein were compared by Fisher’s exact test.
Mean values of independent groups were compared with Student’s t-test.
The level of signiﬁcance was 0.05 (two-sided). This was an exploratory
analysis, thus, no correction for multiple testing was applied. Under this
restriction and taking unequal group sizes into account, standardized
differences (mean difference/standard deviation) of 0.38 and differences in
proportions of 15%–20% could be shown with a power of 80%. With 247
events for OS and 293 events for PFS, hazard ratios of 1.60 and 1.53,
respectively, could be detected with a power of 80%. Commercially
available software was used (SPSS for Window, release 18.0).
results
patient characteristics
Data on MD were available from 71 centers: on CSF in 365
patients (69.4%) of whom 361 (68.6%) were evaluated by CSF
cytomorphology, and 152 (28.9%) by PCR. Data on MD on
MRI were available for 415 (78.9%) patients. Data on CSF
protein levels were available in 304 (57.8%) patients and on
CSF cell count in 290 (55.1%) patients.
Major patient characteristics and therapy are presented in
Table 1. No signiﬁcant difference between MD+ and MD−
patients was observed for any parameter. When initial therapy
was compared, MD+ patients were treated more frequently
with HDMTX as monotherapy and signiﬁcantly less frequently
with HDMTX/IFO than MD− patients (P = 0.05).
detection of MD
CSF cytomorphology was positive in 44 of 361 (12.2%),
suspicious in 23 (6.4%) and negative in 294 (81.4%) patients.
PCR was monoclonal in 16 of 152 (10.5%) and polyclonal in
102 of 152 (67.1%) patients; no IgH-speciﬁc ampliﬁcation
products were found in 34 (22.4%) patients. Table 2 shows the
comparison of PCR results with those of cytomorphologic CSF
examination as a reference. Of 17 patients with positive CSF
cytomorphology and PCR results available, a monoclonal PCR
product was detected in only 5. Conversely, of 82 patients with
inconsistent or negative CSF cytomorphology, a monoclonal
IgH PCR product was found in 10. Of 15 patients with
monoclonal B-cell populations and data on CSF
cytomorphology, positive cytomorphology was found in
only 5, whereas of 84 patients lacking B-cell clonality after IgH
PCR, 12 were cytomorphologically positive.
Leptomeningeal enhancement was present in 17 patients (4.1%)
and absent in 398 (95.9%). Table 3 shows the comparison of MRI
with cytomorphologic ﬁndings. Of 14 patients with MD on MRI
and data on CSF cytomorphology, only 7 were cytomophologically
positive; of 34 patients with positive CSF cytomorphology and
MRI results available, only 7 had MD in MRI.
Considering any of the three methods used, MD was
detected in a total of 65 of 415 patients (15.7%).
Elevated CSF protein was found in 77.8% of MD+ patients
and in 67% of MD− patients (P = 0.22). Elevated CSF cell
count was signiﬁcantly more frequent in MD+ patients: 69.6%
versus 39.7% (P < 0.0001).
outcome
The median follow-up of all patients was 50.7 months.
Median PFS in the MD+ group was 6.7 months [95%
conﬁdence interval (CI) 0–14.5] versus 8.3 months (95% CI 5.7–
10.8) in MD− patients (P = 0.95) and in those with undetermined
MD status 4.5 months (95% CI 2.1–6.9) (Figure 1A). No
signiﬁcant differences were found in responders to HDMTX-
based primary chemotherapy (complete and partial remission) for
PFS when MD+ patients were compared with MD− within one
treatment arm (WBRT and no WBRT). MD+ patients with
WBRT had a median PFS of 33.8 months as compared with 20.2
months in patients without WBRT; this difference, however, was
not signiﬁcant (P = 0.351).
OS was not affected by treatment arm in the G-PCNSL-SG1
trial; thus, patients were combined for OS analysis. Median OS
of MD+ and MD− patients was 21.5 months (95% CI 16.8–
26.1) versus 24.9 (17.5–32.3) (P = 0.98) and that of
undetermined MD status 15.9 months (95% CI 8.0–23.7),
respectively (Figure 1B).
Patients with positive CSF cytomorphology had a median
PFS of 5.9 months (1.4–10.4) and those without MD on
cytomorphologic CSF examination 8.3 (5.6–10.99) (P = 0.89);
the median OS was 20.5 months (14.8–26.3) and 24.1 months
(17.4–30.8), respectively (P = 0.64) (supplemental Figure S1,
available at Annals of Oncology online). PFS and OS were not
signiﬁcantly different in patients with elevated CSF cell count
or elevated CSF protein as compared with those with normal
CSF values.
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discussion
The MD frequency in this analysis was relatively low and
comparable to 7%–29% previously found by cytomorphologic
CSF examination alone in smaller series [2–12, 18, 19].
However, in a study with repeated CSF examination and
meningeal biopsy, a much higher MD frequency of 42% was
detected [1]. In that study, all patients with pathological
evidence of meningeal inﬁltration had negative CSF
cytomorphology indicating that the absence of malignant
lymphocytes on a CSF specimen does not exclude the presence
of meningeal inﬁltration. Autopsy studies reveal that
parenchymal lesions of PCNSL are always in contact with
either leptomeninges or the ependymal surface [20, 21]. This
data suggest that methods routinely used for MD detection in
PCNSL may underestimate this condition. Pretreatment with
steroids in many of our patients—similar to other studies—
might additionally have hampered the MD diagnostics;
however, the proportion of patients on steroids was not
signiﬁcantly different in MD+ and MD− patients (Table 1).
Diagnostic methods for MD detection used in this study are
nowadays routinely used in lymphoma patients by many
clinicians; however, their value has not been clearly deﬁned. In
accordance with our previous analyses [13, 14], a remarkably
high rate of discordant ﬁndings between the three diagnostic
methods used were found. In lymphoma, false-positive CSF
Table 1 Patients’ characteristics and therapy
Characteristics Total no. of patients MD undetermined MD+ MD− P (MD+ versus MD−)
No. of patients 526 161 65 300
Age (years)
Median/range 65/29–84 61/22–83 63/19–80 0.17
KPS 438 70 80 70 0.11
Male/female ratio 526 96/65 34/31 169/131 0.58
MSKCC score 452
1 84 23 (19.8%) 17 (29.5%) 44 (15.8%) 0.13
2 218 57 (49.1%) 27 (46.6%) 134 (48.2%)
3 150 36 (31%) 14 (24.1%) 100 (35.8%)
LDH elevated 307 36 (37.9%) 13 (36.1%) 60 (29.1%) 0.31
No. of lesions 431
0–1 262 80 (64%) 19 (54.3%) 163 (60%) 0.546
≥2 lesions 169 45 (36%) 16 (45.7%) 108 (40%)
Symptoms
None 51 14 (10.2%) 8 (13.6%) 29 (9.8%) 0.36
Headache 137 42 (33.6%) 13 (22.4%) 82 (28.7%) 0.42
Brain pressure 34 11 (9.2%) 2 (3.5%) 21 (7.4%) 0.39
Hemisymptoms 180 45 (36.6%) 16 (27.1%) 119 (41.2%) 0.06
Cognitive dysfunctiona 242 67 (55.8%) 33 (55.9%) 142 (49.7%) 0.39
Cranial nerves 76 13 (11.1) 11 (19.6%) 52 (18.6%) 0.85
Cerebellar 75 18 (14.9%) 5 (8.6%) 52 (18.3%) 0.08
Epilepsia 53 16 (13.1%) 5 (8.6%) 32 (11.1%) 0.82
Organic psychosyndrome 198 51 (40.8%) 22 (37.3%) 125 (43.3%) 0.47
Steroids before diagnostics 526
Unknown 130 39 (24.2%) 25 (38.5%) 66 (22%) 0.23
No 134 35 (19.9%) 17 (26.2%) 82 (27.3%)
Yes 262 87 (54%) 23 (35.4%) 152 (50.7%)
Therapy 526
HDMTX versus 401 115 (71.4%) 57 (87.7%) 229 (76.3%) 0.05
HDMTX/IFO 125 46 (28.5%) 8 (12.3%) 71 (23.7%)
Median total MTX dose (4 g per
cycle = 100%, maximum 600%)
387% 492.5% 455% 0.71
0.52
WBRT 245 77 (47.8%) 34 (52.3%) 134 (44.7%)
aClinically evident.
HDMTX, high-dose methotrexate; KPS, Karnofsky performance score; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering Cancer Center;
MTX, methotrexate; WBRT, whole-brain radiotherapy.
Table 2 Comparison cerebrospinal ﬂuid cytomorphology versus PCR
Cytomorphology PCR
monoclonal
(N = 16)
PCR
polyclonal
(N = 102)
No
ampliﬁcation
(N = 34)
No
PCR
(N = 374)
Positive (N = 44) 5 12 2 25
Negative (N = 317) 10 72 27 208
Unknown (N = 165) 1 18 5 141
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cytomorphology results might be caused by the
misinterpretation of reactive lymphocytes as lymphoma cells,
whereas false-negative results might be due to the paucity of
tumor cells. PCR is frequently difﬁcult to perform in PCNSL as
compared with systemic lymphoma due to its high mutational
frequency preventing annealing of primers [22, 23]. The
relatively low sensitivity of neuroimaging for MD detection in
malignant lymphoma is well known. Moreover, spinal
neuroimaging has not routinely been carried out.
Immunocytologic CSF evaluation was not routinely carried
out in this trial. The study was designed in 1999 when it was
not considered feasible in the context of a nation-wide
multicenter trial. CSF ﬂow cytometry was reported to detect
MD in systemic lymphoma more frequently than CSF
cytomorphology; however, the prognostic impact of a positive
ﬁnding is less clear [24–26]. In a monocenter cohort, MD was
detected by CSF ﬂow cytometry in only one of 32 PCNSL
patients evaluated; however, >50% of these patients were on
steroids at the time of analysis [27]. The diagnostic and
prognostic value of CSF immunophenotyping in PCNSL still
remains to be deﬁned.
No signiﬁcant association of MD with any clinical
characteristic tested was found in this study. Moreover, clinical
symptomatology did not differ between MD+ and MD−
patients indicating that it is no guide to the presence of MD.
CSF protein elevation was not associated with MD in this
trial. This is in contrast to a previous study where elevated CSF
protein was signiﬁcantly associated with leptomeningeal tumor
[1]. We found a signiﬁcant association with CSF pleocytosis,
which may reﬂect the association of meningeal compartment
involvement with higher tumor burden. This ﬁnding is in
accordance with our previous results [13, 16].
We found impact neither of CSF protein elevation nor CSF
pleocytosis on survival. This is in contrast to two retrospective
analyses reporting CSF protein elevation as a negative
prognostic factor in PCNSL [2, 28]. Moreover, no impact on
outcome for MD deﬁned by any of the methods used alone or
in combination was found which is consistent with the
literature [1, 2, 8, 10, 11] and apparently does not support
CSF-directed treatment in PCNSL. This is also suggested by
two retrospective analyses in which no difference in survival
was found between patients who received intrathecal
chemotherapy in addition to systemic treatment and those who
did not [7, 28]. On the other hand, treatment against the
leptomeninges was signiﬁcantly associated with longer freedom
from relapse in a prospective study with 96 patients [1].
Moreover, an excellent outcome with a median OS of 50
months and 57% of patients <60 years being alive after a
median follow-up of 100 months was achieved with a
chemotherapy-only regimen including intraventricular
chemotherapy (Bonn protocol) [29]. These results could not be
reproduced when intraventricular chemotherapy was omitted
[30]. Intraventricular chemotherapy in the Bonn protocol was
much more intensive than in the retrospective analyses
reporting no impact of CSF treatment on outcome, suggesting
that the different ﬁndings may be due to different dosing. All
these data may indicate that MD can be present in more
PCNSL patients than routinely identiﬁed and serve as a
reservoir for lymphoma cells not adequately reached by
systemic chemotherapy alone without intra-CSF treatment.
Table 3 Comparison CSF cytomorphology versus neuroimaging
Cytomorphology Radiological MD,
N = 17
No radiological MD,
N = 398
No data,
N = 111
Positive
(N = 44)
7 27 10
Negative
(N = 317)
7 264 46
Unknown
(N = 165)
3 107 55
CSF, cerebrospinal ﬂuid; MD, meningeal dissemination.
Figure 1. Progression-free survival (A) and overall survival (B) (in months) for patients without MD (MD−) versus those with MD (MD+) versus those
with MD status undetermined. MD, meningeal dissemination.
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Interestingly, in the present trial patients who did not have MD
assessed had a relatively poor outcome. It may be speculated if
this was due to their relatively high median age of 65 years or
to the fact that the sickest patients were not tapped.
Lack of data on MD in a substantial proportion of our study
patients represents a limitation of this analysis. Lumbar
puncture was not carried out in this trial in patients with
suspected elevated brain pressure and at patient’s refusal. CSF
examination by PCR was not obligatory and was not done in
all centers. To minimize this bias, we compared major
prognostic factors such as age, KPS, MSKCC, number of brain
lesions and LDH in serum in MD−, MD+ and MD
undetermined patients and found no signiﬁcant differences
between these groups, suggesting that our results are not biased
by patients’ selection. The lack of central MD diagnostics
(except for IgH PCR) is a further limitation of this study.
Lastly, pretreatment with steroids might have substantially
impacted the outcome analyses in our study. Steroids are
lymphotoxic and might have masked MD in some patients
who might have been falsely classiﬁed negative and negatively
impacted the outcome of the MD− group blurring the
difference to MD+ patients. Nevertheless, no signiﬁcant
association between pretreatment with steroids and MD
detection was found in this trial.
In summary, MD is infrequently detectable by current
methods in PCNSL and did not impact survival in this trial. It
can be speculated that better diagnostic tools and withholding
steroids until the completion of the diagnostic work-up would
help to diagnose this condition more accurately.
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Rituximab induction immunotherapy for ﬁrst-line
low-tumor-burden follicular lymphoma: survival
analyses with 7-year follow-up
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Background: The purpose of this study was to report long-term results of rituximab induction monotherapy in
patients with low-tumor-burden follicular lymphoma (LTBFL).
Patients and methods: Of 49 ﬁrst-line LTBFL patients who received weekly doses of rituximab (375 mg/m2), 46
have been followed with a long-term analysis of clinical and molecular responses.
Results: Best clinical response (at any staging within a year following treatment) was 80%, 24 (52%) patients had
complete or unconﬁrmed complete response, 13 (28%) had partial response and 9 (20%) had stable or progressive
disease. Of 31 patients having a positive bcl2-JH rearrangement, 15 (48%) became negative following treatment.After
83.9 months of follow-up (95% conﬁdence interval 6.4–92.8 months), the median progression-free survival is 23.5
months and overall survival (OS) is 91.7%. Five patients died (one progression, one myelodysplasia, one diffuse large
B-cell lymphoma and two solid tumors). Seven patients (15%) are progression-free including ﬁve who are bcl2
informative. No unexpected long-term adverse event has been observed.
Conclusion: A signiﬁcant proportion of patients remain progression-free 7 years after a single 4-dose rituximab
treatment in ﬁrst-line LTBFL. The 7-year overall survivalOS is very high in this selected population of patients.
Key words: follicular lymphoma, induction monotherapy, low-burden, rituximab
introduction
Although a number of standard chemotherapeutic and
immunotherapeutic agents are active in the treatment of
patients with follicular lymphoma (FL), these treatments do
not cure the patient. In patients with low-tumor-burden and
without adverse prognostic factors, three randomized studies
failed to show any survival beneﬁt of chemotherapy compared
with the observation [1–3]. Hence, watchful waiting is
currently considered as the standard strategy, until clinical
signs or symptoms warrant intervention [4, 5].
Rituximab (MabThera®) is a chimeric murine/human anti-
CD20 monoclonal antibody capable of lysing CD20+
lymphoma cells through multiple mechanisms of action,
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